References
ACGIH (American Conference of Governmental Industrial Hygienists). 2006. Beryllium and Compounds. Cincinnati, OH: American Conference of Governmental Industrial Hygienists.
ACGIH (American Conference of Governmental Industrial Hygienists). 2007. Threshold Limit Values for Chemical Substances and Physical Agents and Biological Exposure Indices. Cincinnati, OH: American Conference of Governmental Industrial Hygienists.
Acton, R.T. 2001. The major histocompatibility complex. Pp. 6.1-6.13 in Clinical Immunology Principles and Practice, 2nd Ed., R.R. Rich, T.A. Fleisher, W.T. Shearer, B.L. Kotzin, and H.W. Schroeder II, eds. London: Mosby.
AIHA (American Industrial Hygiene Association). 1964. Beryllium and its compounds. Am. Ind. Hyg. Assoc. J. 25.
Amicosante, M., and A.P. Fontenot. 2006. T cell recognition in chronic beryllium disease. Clin. Immunol. 121(2):134-143.
Amicosante, M., N. Sanarico, F. Berretta, J. Arroyo, G. Lombardi, R. Lechler, V. Colizzi, and C. Saltini. 2001. Beryllium binding to HLA-DP molecule carrying the marker of susceptibility to berylliosis glutamate β69. Hum. Immunol. 62(7):686-693.
Amicosante, M., D. Deubner, and C. Saltini. 2005. Role of the berylliosis-associated HLA-DPGlu69 supratypic variant in determining the response to beryllium in a blood T-cells beryllium-stimulated proliferation test. Sarcoidosis Vasc. Diffuse Lung Dis. 22(3):175-179.
Andersen, O. 1983. Effects of coal combustion products and metal compounds on sister chromatid exchange (SCE) in a macrophage cell line. Environ. Health Perspect. 47:239-253.
Andrews, J.L., H. Kazemi, and H.L. Hardy. 1969. Patterns of lung dysfunction in chronic beryllium disease. Am. Rev. Respir. Dis. 100(6):791-800.
ANSI (American National Standards Institute). 1970. Acceptable concentrations of beryllium and beryllium compounds (Z37.29-1970). New York: American National Standards Institute.
Apostoli, P., and K.H. Schaller. 2001. Urinary beryllium—a suitable tool for assessing occupational and environmental beryllium exposure? Int. Arch. Occup. Environ. Health 74(3)162-166.
Arlauskas, A., R.S. Baker, A.M. Bonin, R.K. Tandon, P.T. Crisp, and J. Ellis. 1985. Mutagencity of metal ions in bacteria. Environ. Res. 36(2):379-388.
Aronchick, J.M., M.D. Rossman, and W.T. Miller. 1987. Chronic beryllium disease: diagnosis, radiographic findings, and correlation with pulmonary function tests. Radiology 163(3):677-682.
Ashby, J., M. Ishidate, Jr., G.D. Stoner, M.A. Morgan, F. Ratpan, and R.D. Callander. 1990. Studies on the genotoxicity of beryllium sulphate in vitro and in vivo. Mutat. Res. 240(3):217-225.
ATSDR (Agency for Toxic Substances and Disease Registry). 2002. Toxicological Profile for Beryllium (Update). U.S. Department of Health and Human Services, Public Health Service, Atlanta, GA. September 2002.
Balkisson, R.C., and L.S. Newman. 1999. Beryllium copper alloy (2%) causes chronic beryllium disease. J. Occup. Environ. Med. 41(4):304-308.
Barna, B.P., T. Chiang, S.G. Pillarisetti, and S.D. Deodhar. 1981. Immunologic studies of experimental beryllium lung disease in the guinea pig. Clin. Immunol. Immunopathol. 20(3):402-411.
Barnard, A.E., J. Torma-Krajewski, and S.M. Viet. 1996. Retrospective beryllium exposure assessment at the Rocky Flats Environmental Technology Site. Am. Ind. Hyg. Assoc. J. 57(9):804-808.
Bekris, L.M., H.M. Viernes, F.M. Farin, L.A. Maier, T.J. Kavanagh, and T.K. Takaro. 2006. Chronic beryllium disease and glutathione biosynthesis genes. J. Occup. Environ. Med. 48(6):599-606.
Belinsky, S.A., S.S. Snow, K.J. Nikula, G.L. Finch, C.S. Tellez, and W.A. Palmisano. 2002. Aberrant CpG island methylation of the p16INK4a and estrogen receptor genes in rat lung tumors induced by particulate carcinogens. Carcinogenesis 23(2):335-339.
Bello, D., T.J. Smith, S.R. Woskie, R.P. Streicher, M.F. Boeniger, C.A. Redlich, and Y. Liu. 2006. An FTIR investigation of isocyanate skin absorption using in vitro guinea pig skin. J. Environ. Monit. 8(5):523-529.
Belman, S. 1969. Beryllium binding of epidermal constituents. J. Occup. Med. 11(4):175-183.
Bencko, V., M. Brezina, B. Benes, and M. Cikrt. 1979. Penetration of beryllium through the placenta and its distribution in the mouse. J. Hyg. Epidemiol. Microbiol. Immunol. 23(4):361-367.
Benson, J.M., A.M. Holmes, E.B. Barr, K.J. Nikula, and T.H. March. 2000. Particle clearance and histopathology in lungs of C3H/HeJ mice administered beryllium/copper alloy by intratracheal instillation. Inhal. Toxicol. 12(8):733-749.
Berlin, J.M., J.S. Taylor, J.E. Sigel, W.F. Bergfeld, and R.A. Dweik. 2003. Beryllium dermatitis. J. Am. Acad. Dermatol. 49(5):939-941.
Bill, J.R., D.G. Mack, M.T. Falta, L.A. Maier, A.K. Sullivan, F.G. Joslin, A.K. Martin, B.M. Freed, B.L. Kotzin, and A.P. Fontenot. 2005. Beryllium presentation to CD4+ T cells is dependent on a single amino acid residue of the MHC class II β-chain. J. Immunol. 175(10):7029-7037.
Bost, T.W., D.W. Riches, B. Schumacher, P.C. Carré, T.Z. Khan, J.A. Martinez, and L.S. Newman. 1994. Alveolar macrophages from patients with beryllium disease and sarcoidosis express increased levels of mRNA for tumor necrosis factor-α and interleukin-6 but not interleukin-1β. Am. J. Respir. Cell Mol. Biol. 10(5):506-513.
Brooks, A.L., W.C. Griffith, N.F. Johnson, G.L. Finch, and R.G. Cuddihy. 1989. The induction of chromosome damage in CHO cells by beryllium and radiation given alone and in combination. Radiat. Res. 120(3):494-507.
Brown, S.C., M.F. Schonbeck, D. McClure, A.E. Barón, W.C. Navidi, T. Byers, and A.J. Ruttenber. 2004. Lung cancer and internal lung doses among plutonium workers at the Rocky Flats plant: A case-control study. Am. J. Epidemiol. 160(2):163-172.
Campbell, R.O. 1961. A study of beryllium exposure at a high explosive assembly test facility. Am. Ind. Hyg. Assoc. 22:385-391.
Carpenter, A.V., W.D. Flanders, E.L. Frome, W.G. Tankersley, and S.A. Fry. 1988. Chemical exposures and central nervous system cancers: A case-control study among workers at two nuclear facilities. Am. J. Ind. Med. 13(3):351-362.
Cholak, J., and D.M. Hubbard. 1948. Spectrographic determination of beryllium in biological material and in air. Anal. Chem. 20(1):73-76.
Cianciara, M.J., A.P. Volkova, N.L. Aizina, and O.G. Alekseeva. 1980. A study of humoral and cellular responsiveness in a population occupationally exposed to beryllium. Int. Arch. Occup. Environ. Health 45(1):87-94.
Clary, J.J., C.R. Hopper, and H.E. Stokinger. 1972. Altered adrenal function as an inducer of latent chronic beryllium disease. Toxicol. Appl. Pharmacol. 23(3):365-375.
Clary, J.J., L.S. Bland, and H.E. Stokinger. 1975. The effect of reproduction and lactation on the onset of latent chronic beryllium disease. Toxicol. Appl. Pharmacol. 33(2):214-221.
Cohen, B.S. 1991. Air sampling. Pp. 211-224 in Beryllium: Biomedical and Environmental Aspects, M.D. Rossman, O.P. Preuss, and M.B. Powers, eds. Baltimore, MD: Williams & Wilkins.
Cohen, B.S., N.H. Harley, C.A. Martinelli, and M. Lippmann. 1983. Sampling artifacts in the breathing zone. Pp. 347-360 in Proceedings of the International Symposium on Aerosols in the Mining and Industrial Work Environment, B.Y.H. Liu and V.A. Marple, eds. Minneapolis, MN: Ann Arbor Press.
Cotes, J.E., J.C. Gilson, C.B. McKerrow, and P.D. Oldham. 1983. A long-term follow-up of workers exposed to beryllium. Br. J. Ind. Med. 40(1):13-21.
Cullen, M.R., J.R. Kominsky, M.D. Rossman, M.G. Cherniack, J.A. Rankin, J.R. Balmes, J.A. Kern, R.P. Daniele, L. Palmer, G.P. Naegel, K. McManus, and R. Cruz. 1987. Chronic beryllium disease in a precious metal refinery. Clinical epidemiologic and immunologic evidence for continuing risk from exposure to low level beryllium fume. Am. Rev. Respir. Dis. 135(1):201-208.
Cummings, K.J., D.C. Deubner, G.A. Day, P.K. Henneberger, M.M. Kitt, M.S. Kent, K. Kreiss, and C.R. Schuler. 2007. Enhanced preventive programme at a beryllium oxide ceramics facility reduces beryllium sensitization among new workers. Occup. Environ. Med. 64(2):134-140.
Curtis, G.H. 1951. Cutaneous hypersensitivity due to beryllium: A study of thirteen cases. AMA Arch. Derm. Syphilol. 64(4):470-482.
Curtis, G.H. 1959. The diagnosis of beryllium disease, with special reference to the patch test. AMA Arch. Ind. Health 19(2):150-153.
Daniloff, E.M., D.A. Lynch, B.B. Bartelson, J.D. Newell, Jr., S.M. Bernstein, and L.S. Newman. 1997. Observer variation and relationship of computed tomography to severity of beryllium disease. Am. J. Respir. Crit. Care Med. 155(6):2047-2056.
Dattoli, J.A., J. Lieben, and J. Bisbing. 1964. Chronic beryllium diease. A follow-up study. J. Occup. Med. 6:189-194.
Day, G.A., M.D. Hoover, A.B. Stefaniak, R.M. Dickerson, E.J. Peterson, and N.A. Esmen. 2005. Bioavailability of beryllium oxide particles: An in vitro study in the murine J774A.1 macrophage cell line model. Exp. Lung Res. 31(3):341-360.
Day, G.A., A.B. Stefaniak, A. Weston, and S.S. Tinkle. 2006. Beryllium exposure: Dermal and immunological considerations. Int. Arch. Occup. Environ. Health 79(2):161-164.
Day, G.A., A. Dufresne, A.B. Stefaniak, C.R. Schuler, M.L. Stanton, W.E. Miller, M.S. Kent, D.C. Deubner, K. Kreiss, and M.D. Hoover. 2007. Exposure pathway assessment at a copper-beryllium alloy facility. Ann. Occup. Hyg. 51(1):67-80.
Deubner, D., M. Kelsh, M. Shum, L. Maier, M. Kent, and E. Lau. 2001a. Beryllium sensitization, chronic beryllium disease, and exposures at a beryllium mining and extraction facility. Appl. Occup. Environ. Hyg. 16(5):579-592.
Deubner, D.C., M. Goodman, and J. Iannuzzi. 2001b. Variability, predictive value, and uses of the beryllium lymphocyte proliferation test (BLPT): Preliminary analysis of the ongoing workforce survey. Appl. Occup. Environ. Hyg. 16(5):521-526.
Deubner, D.C., J.L. Lockey, P. Kotin, M.B. Powers, F. Miller, A.E. Rogers, and D. Trichopoulos. 2001c Re: Lung-cancer case-control study of beryllium workers. Am. J. Ind. Med. 40(3):284-285.
DiPaolo, J.A. and B.C. Casto. 1979. Quantitative studies of in vitro morphological transformation of Syrian hamster cells by inorganic metal salts. Cancer Res. 39(3):1008-1013.
DOE (U.S. Department of Energy). 1996. A Comprehensive Assessment of Toxic Emissions from Coal-Fired Power Plants: Topical Report. DOE/MC/30097-5321. Prepared for U.S. Department of Energy, Office of fossil Energy, Morgantown, WV, by University of North Dakota, Grand Forks, ND [online]. Available: http://www.netl.doe.gov/technologies/coalpower/cctc/cctdp/bibliography/misc/pdfs/haps/M97002069.pdf [accessed June 21, 2007].
Donaldson, H.M., and W.T. Stringer. 1980. Beryllium sampling methods. Am. Ind. Hyg. Assoc. J. 41(2):85-90.
Dotti, C., M.R. D’Apice, P. Rogliani, G. Novelli, C. Saltini, and M. Amicosante. 2004. Analysis of TNF-α promoter polymorphisms in the susceptibility to beryllium hypersensitivity. Sarcoidosis Vasc. Diffuse Lung Dis. 21(1):29-34.
Drury, J.S., C.R. Shriner, E.B. Lewis, L.E. Towill, and A.S. Hammons. 1978. Reviews of the Environmental Effects of Pollutants: VI. Beryllium. EPA-600/1-78-028. U.S. Environmental Protection Agency, Cincinnati, OH (as cited in ATSDR 2002).
Dunkel, V.C, E. Zeiger, D. Brusick, E. McCoy, D. McGregor, K. Mortelmans, H.S. Rosenkranz, and V.F. Simmon. 1984. Reproducibility of microbial mutagenicity assays: I. Tests with Salmonella typhimurium and Escherichia coli using a standardized protocol. Environ. Mutagen. 6(Suppl. 2):1-251.
Dutra, F.R., E.J. Largent, and J.L. Roth. 1951. Osteogenic sarcoma after inhalation of beryllium oxide. AMA Arch. Pathol. 51(5):473-479.
Dylevoi, M.V. 1990. Evaluation of the DNA-damaging action of the carcinogenic metal beryllium by means of bacterial repair test [in Russian]. Mikrobiol. Zh. 52(1):34-38 (as cited in EPA 1998a).
EBI (European Bioinformatics Institute). 2007. EBI databases [online]. Available: http://www.ebi.ac.uk/Databases/ [accessed April 2007].
Eidson, A.F., M.D. Hoover, B.J. Greenspan, and C.A. Cornell. 1984. Characteristics of beryllium aerosols for toxicity studies. In Annual Report of the Inhalation Toxicology Research Institute, October 1, 1983-September 30, 1984, R.A. Guilmette, and M.A. Medinsky, eds. Report No. LMF-113. Inhalation Toxicology Research Institute, Lovelace Biomedical and Environmental Research Institute, Albuquerque, NM.
Eisenbud, M., R.C. Wanta, C. Dustan, L.T. Steadman, W.B. Harris, and B.S. Wolf. 1949. Non-occupational berylliosis. J. Ind. Hyg. Toxicol. 31:281-294.
Eidson, A.F., A. Taya, G.L. Finch, M.D. Hoover, and C. Cook. 1991. Dosimetry of beryllium in cultured canine pulmonary alveolar macrophages. J. Toxicol. Environ. Health 34(4):433-448.
Eisenbud, M. 1982. Origins of the standards for control of beryllium disease (1947-1949). Environ. Res. 27(1):79-88.
Eisenbud, M., and J. Lisson. 1983. Epidemiological aspects of beryllium-induced nonmalignant lung disease: A 30-year update. J. Occup. Med. 25(3):196-202.
Eisenbud, M., R.C. Wanta, C. Dustan, L.T. Steadman, W.B. Harris, and B.S. Wolf. 1949. Non-occupational berylliosis. J. Ind. Hyg. Toxicol. 31:282-294.
Emond, C., J.P. Robin, R. Breton, S. Philippe, and J. Zayed. 2007. Dermal exposure to beryllium: A pilot case study. J. Toxicol. Environ. Health A 70(6):529-533.
EPA (U.S. Environmental Protection Agency). 1987. Health Assessment Document for Beryllium. EPA/600/8-84/026F. Office of Health and Environmental Assessment, U.S. Environmental Protection Agency, Washington, DC (as cited in ATSDR 2002).
EPA (U.S. Environmental Protection Agency). 1991. Drinking Water Criteria Document for Beryllium. NTIS PB92-173301. U.S. Environmental Protection Agency, Washington DC.
EPA (U.S. Environmental Protection Agency). 1998a. Beryllium and Compounds (CASRN 7440-41-7). Integrated Risk Information System, U.S. Environmental Protection Agency [online]. Available: http://www.epa.gov/iris/subst/0012.htm [accessed March 26, 2007].
EPA (U.S. Environmental Protection Agency). 1998b. Toxicological Review of Beryllium and Compounds (CAS No. 7440-41-7) in Support of Summary Information on the Integrated Risk Information System (IRIS). EPA/635/R-98/008. U.S. Environmental Protection Agency, Washington, DC [online]. Available: http://www.epa.gov/iris/toxreviews/0012-tr.pdf [accessed March 26, 2007].
Eskenasy, A. 1979. Experimental pulmonary berylliosis in rabbits sensitized to beryllium sulfate: Contact hypersensitivity. Morphol. Embryol. 25(3):257-262.
Farris, G.M., L.S. Newman, E.L. Frome, Y. Shou, E. Barker, R.C. Habbersett, L. Maier, H.N. Smith, and B.L. Marrone. 2000. Detection of beryllium sensitivity using a flow cytometric lymphocyte proliferation test: The Immuno-Be-LPT. Toxicology 143(2):125-140.
Finch, G.L., J.A. Mewhinney, A.F. Eidson, M.D. Hoover, and S.J. Rothenberg. 1988. In vitro dissolution characteristics of beryllium oxide and beryllium metal aerosols. J. Aerosol. Sci. 19(3):333-342.
Finch, G.L., P.J. Haley, M.D. Hoover, M.B. Snipes, and R.G. Cuddihy. 1994. Responses of rat lungs to low lung burdens of inhaled beryllium metal. Inhal. Toxicol. 6(3):205-224.
Finch, G.L., M.D. Hoover, F.F. Hahn, K.J. Nikula, S.A. Belinksy, P.J. Haley, and W.C. Griffith. 1996. Animal models of beryllium-induced lung disease. Environ. Health Perspect. 104(Suppl. 5):973-979.
Finch, G.L., K.J. Nikula, and M.D. Hoover. 1998a. Dose-response relationships between inhaled beryllium metal and lung toxicity in C3H mice. Toxicol. Sci. 42(1):36-48.
Finch, G.L., T.H. March, F.F. Hahn, E.B. Barr, S.A. Belinsky, M.D. Hoover, J.F. Lechner, K.J. Nikula, and C.H. Hobbs. 1998b. Carcinogenic responses of transgenic heterozygous p53 knockout mice to inhaled 239PuO2 or metallic beryllium. Toxicol. Pathol. 26(4):484-491.
Fireman, E., I. Topilsky, J. Greif, Y. Lerman, Y. Schwarz, A. Man, and M. Topilsky. 1999. Induced sputum compared to bronchoalveolar lavage for evaluating patients with sarcoidosis and non-granulomatous interstitial lung disease. Respir. Med. 93(11):827-834.
Fishbein, L. 1981. Sources, transport and alterations of metal compounds: An overview. I. Arsenic, beryllium, cadmium, chromium, and nickel. Environ. Health Perspect. 40:43-64.
Fontenot, A.P. and L.A. Maier. 2005. Genetic susceptibility and immune-mediated destruction in beryllium-induced disease (review). Trends Immunol. 26:543-549.
Fontenot, A.P., M.T. Falta, B.M. Freed, L.S. Newman, and B.L. Kotzin. 1999. Identification of pathogenic T cells in patients with beryllium-induced lung disease. J. Immunol. 163(2):1019-1026.
Fontenot, A.P., M. Torres, W.H. Marshall, L.S. Newman, and B.L. Kotzin. 2000. Beryllium presentation to CD4+ T cells underlies disease-susceptibility HLA-DP alleles in chronic beryllium disease. Proc. Natl. Acad. Sci. 97(23):12717-12722.
Fontenot, A.P., S.J. Canavera, L. Charavi, L.S. Newman, and B.L. Kotzin. 2002. Target organ localization of memory CD4+ T cells in patients with chronic beryllium disease. J. Clin. Invest. 110(10):1473-1482.
Fontenot, A.P., L. Gharavi, S.R. Bennett, S.J. Canavera, L.S. Newman, and B.L. Kotzin. 2003. CD28 costimulation independence of target organ versus circulating memory antigen-specific CD4+ T cells. J. Clin. Invest. 112(5):776-784.
Fontenot, A.P., B.E. Palmer, A.K. Sullivan, F.G. Joslin, C.C. Wilson, L.A. Maier, L.S. Newman, and B.L. Kotzin. 2005. Frequency of beryllium-specific, central memory CD4+ T cells in blood determines proliferative response. J. Clin. Invest. 115(10):2886-2893.
Fontenot, A.P., T.S. Keizer, M. McCleskey, D.G. Mack, R. Meza-Romero, J. Huan, D.M. Edwards, Y.K. Chou, A.A. Vendenbark, B. Scott, and G.G. Burrows. 2006a. Recombinant HLA-DP2 binds beryllium and tolerizes beryllium-specific pathogenic CD4+ T cells. J. Immunol. 177(6):3874-3883.
Fontenot, A.P., D.M. Edwards, Y.K. Chou, D.G. Mack, D. LaTocha, A.A. Vendenbark, and G.G. Burrows. 2006b. Self-presentation of beryllium by BAL CD4+ T cells: T cell-T cell interactions and their potential role in chronic beryllium disease. Eur. J. Immunol. 36(4):930-939.
Freiman, D.G., and H.L. Hardy. 1970. Beryllium disease. The relation of pulmonary pathology to clinical course and prognosis based on a study of 130 cases from the U.S. Beryllium Case Registry. Human Pathol. 1(1):25-44.
Gaede, K.I., M. Amicosante, M. Schürmann, E. Fireman, C. Saltini, and J. Müller-Quernheim. 2005. Function associated transforming growth factor-β gene polymorphism in chronic beryllium disease. J. Mol. Med. 83(5):397-405.
Goel, K.A., V.P. Agrawal, and V. Garg. 1980. Pulmonary toxicity of beryllium in albino rat. Bull. Environ. Contam. Toxicol. 24(1):59-64.
Gordon, T., and D. Bowser. 2003. Beryllium: Genotoxicity and carcinogenicity. Mutat. Res. 533(1-2):99-105.
Griggs, K. 1973. Toxic metal fumes from mantle-type camp lanterns. Science 181(102):842-843.
Groth, D.H., C. Kommineni, and G.R. Mackay. 1980. Carcinogenicity of beryllium hydroxide and alloys. Environ. Res. 21(1):63-84.
Haley, P.J. 1991. Mechanisms of granulomatous lung disease from inhaled beryllium: The role of antigenicity in granuloma formation. Toxicol. Pathol. 19(4 Part 1):514-525.
Haley, P.J., G.L. Finch, J.A. Mewhinney, A.G. Harmsen, F.F. Hahn, M.D. Hoover, B.A. Muggenburg, and D.E. Bice. 1989. A canine model of beryllium-induced granulomatous lung disease. Lab. Invest. 61(2):219-227.
Haley, P.J., G.L. Finch, M.D. Hoover, and R.G. Cuddihy. 1990. The acute toxicity of inhaled beryllium metal in rats. Fundam. Appl. Toxicol. 15(4):767-778.
Haley, P.J., G.L. Finch, M.D. Hoover, J.A. Mewhinney, D.E. Bice, and B.A. Muggenburg. 1992. Beryllium-induced lung disease in the dog following two exposures to BeO. Environ. Res. 59(2):400-415.
Haley, P.J., K.F. Pavia, D.S. Swafford, D.R. Davila, M.D. Hoover, and G.L. Finch. 1994. The comparative pulmonary toxicity of beryllium metal and beryllium oxide in cynomolgus monkeys. Immunopharmacol. Immunotoxicol. 16(4):627-644.
Hall, R.H., J.K. Scott, S. Laskin, C.A. Stroud, and H.E. Stokinger. 1950. Acute toxicity of inhaled beryllium: Observations correlating toxicity with the physicochemical properties of beryllium oxide dust. Arch. Ind. Hyg. Occup. Med. 2(1):25-48.
Hardy, H.L. 1980. Beryllium disease: A clinical perspective. Environ. Res. 21(1):1-9.
Hardy, H.L., and I.R. Tabershaw. 1946. Delayed chemical pneumonitis occurring in workers exposed to beryllium compounds. J. Ind. Hyg. Toxicol. 28(5):197-211.
Harmsen, A.G., M.D. Hoover, and F.A. Seiler. 1984. Health risk implications of using beryllium in fusion reactors. J. Nuclear Mat. 123:821-826.
Harris, J., B.B. Bartelson, E. Barker, R. Balkissoon, K. Kreiss, and L.S. Newman. 1997. Serum neopterin in chronic beryllium disease. Am. J. Ind. Med. 32(1):21-26.
Hart, B.A., A.G. Harmsen, R.B. Low, and R. Emerson. 1984. Biochemical, cytological, and histological alterations in rat lung following acute beryllium aerosol exposure. Toxicol. Appl. Pharmacol. 75(3):454-465.
Hasan, F.M., and H. Kazemi. 1974. Chronic beryllium disease: a continuing epidemiologic hazard. Chest 65(3):289-293.
Henneberger, P.K., D. Cumro, D.D. Deubner, M.S. Kent, M. McCawley, and K. Kreiss. 2001. Beryllium sensitization and disease among long-term and short-term workers in a beryllium ceramics plant. Int. Arch. Occup. Environ. Health 74(3):167-176.
Henneberger, P.K., S.K. Goe, W.E. Miller, B. Doney, and D.W. Groce. 2004. Industries in the United States with airborne beryllium exposure and estimates of the number of current workers potentially exposed. J. Occup. Environ. Hyg. 1(10):648-659.
Hong-Geller, E., P.E. Pardington, R.B. Cary, N.N. Sauer, and G. Gupta. 2006. Chemokine regulation in response to beryllium exposure in human peripheral blood mononuclear and dendritic cells. Toxicology 218(2-3):216-228.
Hoover, M.D., G.L. Finch, J.A. Mewhinney, and A.F. Eidson. 1990. Release of aerosols during sawing and milling of beryllium metal and beryllium alloys. Appl. Occup. Environ. Hyg. 5(11):787-791.
Hsie, A.W., N.P. Johnson, D.B. Couch, J.R. San Sebastian, J.P. O’Neill, J.D. Hoeschele, R.O. Rahn, and N.L. Forbes. 1979. Quantitative mammalian cell mutagenesis and a preliminary study of the mutagenic potential of metallic compounds. Pp. 55-69 in Trace Metals in Health and Disease: New Roles of Metals in Biochemistry, the Environment, and Clinical/Nutritional Studies, N. Kharasch, ed. New York: Raven Press.
Huang, H., K.C. Meyer, L. Kubai, and R. Auerbach. 1992. An immune model of beryllium-induced pulmonary granulomata in mice. Histopathology, immune reactivity, and flow-cytometric analysis of bronchoalveolar lavage-derived cells. Lab. Invest. 67(1):138-146.
Hyatt, E.C., and M.F. Milligan. 1953. Experiences with unusual materials and operations. Am. Ind. Hyg. Assoc. Q. 14(4):289-293.
Hyatt, E.C., H.F. Schulte, R.N. Mitchell, and E.P. Tangman, Jr. 1959. Beryllium: Hazard evaluation and control in research and development operations. AMA Arch. Ind. Health 19(2):211-220.
IARC (International Agency for Research on Cancer). 1993. Beryllium, Cadmium, Mercury, and Exposures in the Glass Manufacturing Industry. IARC Monographs on the Evaluation of Carcinogenic Risks to Humans, Vol. 58. Lyon, France: World Health Organization.
Infante, P.F., and L.S. Newman. 2004. Beryllium exposure and chronic beryllium disease. Lancet 363(9407):415-416.
Infante, P.F., J.K. Wagoner, and N.L. Sprince. 1980. Mortality patterns from lung cancer and nonneoplastic respiratory disease among white males in the beryllium case registry. Environ. Res. 21(1):35-43.
Ishinishi, N., M. Mizunoe, T. Inamasu, and A. Hisanaga. 1980. Experimental study on carcinogenicity of beryllium oxide and arsenic trioxide to the lung of rats by an intratracheal instillation (in Japanese-author’s translation). Fukuoka Igaku Zasshi. 71(1):19-26.
Johnson, J.S., K. Foote, M. McClean, and G. Cogbill. 2001. Beryllium exposure control program at the Cardiff Atomic Weapons Establishment in the United Kingdom. Appl. Occup. Environ. Hyg. 16(5):619-630.
Joseph, P., T. Muchnok, and T. Ong. 2001. Gene expression profile in BALB/c-3T3 cells transformed with beryllium sulfate. Mol. Carcinog. 32(1):28-35.
Kada, T., K. Hirano, and Y. Shirasu. 1980. Screening of environmental chemical mutagens by the rec-assay system with Bacillus subtilis. Pp. 149-173 in Chemical Mutagens, Principles and Methods for Their Detection, Vol. 6, F.J. de Serres, and A. Hollaender, eds. New York: Plenum Press.
Kanematsu, N., M. Hara, and T. Kada. 1980. Rec assay and mutagenicity studies on metal compounds. Mutat. Res. 77(2):109-116.
Kang, K.Y., D. Bice, E. Hoffmann, R. D’Amato, and J. Salvaggio. 1977. Experimental studies of sensitization to beryllium, zirconium, and aluminum compounds in the rabbit. J. Allergy Clin. Immunol. 59(6):425-436.
Kelleher, P.C., J.W. Martyny, M.M. Mroz, L.A. Maier, A.J. Ruttenber, D.A. Young, and L.S. Newman. 2001. Beryllium particulate exposure and disease relations in a beryllium machining plant. J. Occup. Environ. Med. 43(3):238-249.
Kent, M.S., T.G. Robins, and A.K. Madl. 2001. Is total mass or mass of alveolar-deposited airborne particles of beryllium a better predictor of the prevalence of disease? A preliminary study of a beryllium processing facility. Appl. Occup. Environ. Hyg. 16(5):539-558.
Keshava, N., G. Zhou, M. Spruill, M. Ensell, and T.M. Ong. 2001. Carcinogenic potential and genomic instability of beryllium sulphate in BALB/c-3T3 cells. Mol. Cell. Biochem. 222(1-2):69-76.
Kittle, L.A., R.T. Sawyer, V.A. Fadok, L.A. Maier, and L.S. Newman. 2002. Beryllium induces apoptosis in human lung macrophages. Sarcoidosis Vasc. Diffuse Lung Dis. 19(2):101-113.
Kolanz, M.E. 2001. Introduction to beryllium: Uses, regulatory history, and disease. Appl. Occup. Environ. Hyg. 16(5):559-567.
Kolanz, M.E., A.K. Madl, M.A. Kelsh, M.S. Kent, R.M. Kalmes, and D.J. Paustenbach. 2001. A comparison and critique of historical and current exposure assessment methods for beryllium: Implications for evaluating risk of chronic beryllium disease. Appl. Occup. Environ. Hyg. 16(5):593-614.
Kotin, P. 1994a. Re: The epidemiological evidence on the carcinogenicity of beryllium, by MacMahon. J. Occup. Med. 36(1):25-26.
Kotin, P. 1994b. Reply to letter to the editor from Vaino and Kleihues (1994) on Re: The epidemiological evidence on the carcinogenicity of beryllium, by MacMahon. J. Occup. Med. 36(10):1069-1070.
Kress, J.E., and K.R. Crispell. 1944. Chemical pneumonitis in men working with fluorescent powders containing beryllium. Guthrie Clin. Bull. 13:91-95.
Kreiss, K., L.S. Newman, M.M. Mroz, and P.A. Campbell. 1989. Screening blood test identifies subclinical beryllium disease. J. Occup. Med. 31(7):603-608.
Kreiss, K., S. Wasserman, M.M. Mroz, and L.S. Newman. 1993a. Beryllium disease screening in the ceramics industry. Blood lymphocyte test performance and exposure-disease relations. J. Occup. Med. 35(3):267-274.
Kreiss, K., M.M. Mroz, B. Zhen, J.W. Martyny, and L.S. Newman. 1993b. Epidemiology of beryllium sensitization and disease in nuclear workers. Am. Rev. Respir. Dis. 148(4 Pt 1):985-991.
Kreiss, K., M.M. Mroz, L.S. Newman, J. Martyny, and B. Zhen. 1996. Machining risk of beryllium disease and sensitization with median exposures below 2 μg/m3. Am. J. Ind. Med. 30(1):16-25.
Kreiss, K., M.M. Mroz, B. Zhen, H. Wiedemann, and B. Barna. 1997. Risks of beryllium disease related to work processes at a metal, alloy, and oxide production plant. Occup. Environ. Med. 54(8):605-612.
Kreiss, K., G.A. Day, and C.R. Schuler. 2007. Beryllium: A modern industrial hazard. Annu. Rev. Public Health 28:259-277.
Kriebel, D., N.L. Sprince, E.A. Eisen, and I.A. Greaves. 1988. Pulmonary function in beryllium workers: Assessment of exposure. Br. J. Ind. Med. 45(2):83-92.
Kuroda, K., G. Endo, A. Okamoto, Y.S. Yoo, and S. Horiguchi. 1991. Genotoxicity of beryllium, gallium and antimony in short-term assays. Mutat. Res. 264(4):163-170.
Larramendy, M.L., N.C. Popescu, and J.A. DiPaolo. 1981. Induction by inorganic metal salts of sister chromatid exchanges and chromosome aberrations in human and Syrian hamster cell strains. Environ. Mutagen. 3(6):597-606.
Lawrence, D.A., M.J. McCabe. 2002. Immunomodulation by metals. Int. Immunopharmacol. 2(2-3):293-302.
Levy, P.S., H.D. Roth, P.M.T. Hwang, and T.E. Powers. 2002. Beryllium and lung cancer: A reanalysis of a NIOSH cohort mortality study. Inhal. Toxicol. 14(10):1003-1015.
Levy, P.S., H.D. Roth, and D.C. Deubner. 2007. Exposure to beryllium and occurrence of lung cancer: A reexamination of findings from a nested case-control study. J. Occup. Environ. Med. 49(1):96-101.
Lieben, J., and F. Metzner. 1959. Epidemiological findings associated with beryllium extraction. Am. Ind. Hyg. Assoc. J. 20(6):494-499.
Lieben, J., and R.R. Williams. 1969. Respiratory disease associated with beryllium refining and alloy fabrication: 1968 follow-up. J. Occup. Med. 11(9):480-485.
Lindeken, C.L., and O.L. Meadors. 1960. Control of beryllium hazards. Am. Ind. Hyg. Assoc. J. 21(3):245-251.
Litvinov, N.N., P.F. Bugryshev, and V.F. Kazenashev. 1975. Toxic properties of some soluble compounds of beryllium (based on data from experimental morphological research [in Russian]. Gig. Tr. Prof. Zabol. 7:34-37.
Litvinov, N.N., V.F. Kazenashev, and P.F. Bugryshev. 1983. Blastomogenic activities of various beryllium compounds [in Russian]. Eksp. Onkol. 5:23-26.
Litvinov, N.N., V.A. Popov, T.V. Vorozheikina, V.F. Kazenashev, and P.F. Bugryshev. 1984. Data for more precise determination of the maximum allowable concentration of beryllium in the air of the workplace [in Russian]. Gig. Tr. Prof. Zabol. 1:34-37.
Lombardi, G., C. Germain, J. Uren, M.T. Fiorillo, R.M. du Bois, W. Jones-Williams, C. Saltini, R. Sorrentino, and R. Lechler. 2001. HLA-DP allele-specific T cell responses to beryllium account for DP-associated susceptibility to chronic beryllium disease. J. Immunol. 166(5):3549-3555.
Machle, W., E. Beyer, and F. Gregorius. 1948. Berylliosis. Occup. Med. 5:671-683.
MacMahon, B. 1994. The epidemiological evidence on the carcinogenicity of beryllium in humans. J. Occup. Med. 36(1):15-24.
Maier, L.A. 2002. Genetic and exposure risks for chronic beryllium disease. Clin. Chest Med. 23:827-839.
Maier, L.A. 2007. Pathogenesis of Chronic Beryllium Disease and Genetic Susceptibility. Presentation at the Second Meeting on Beryllium Alloy Exposures, April 5, 2007, Washington, DC.
Maier, L.A., M.V. Raynolds, D.A. Young, E.A. Barker, and L.S. Newman. 1999. Angiotensin-1 converting enzyme polymorphisms in chronic beryllium disease. Am. J. Respir. Crit. Care Med. 159(4 Pt 1):1342-1350.
Maier, L.A., R.T. Sawyer, R.A. Bauer, L.A. Kittle, P. Lympany, D. McGrath, R. duBois, E. Daniloff, C.S. Rose, and L.S. Newman. 2001. High beryllium-stimulated TNF-α is associated with the -308 TNF-α promoter polymorphism and with clinical severity in chronic beryllium disease. Am. J. Respir. Crit. Care Med. 164(7):1192-1199.
Maier, L.A., L.A. Kittle, M.M. Mroz, and L.S. Newman. 2003a. Beryllium-stimulated neopterin as a diagnostic adjunct in chronic beryllium disease. Am. J. Ind. Med. 43(6):592-601.
Maier, L.A., D.S. McGrath, H. Sato, P. Lympany, K. Welsh, R. du Bois, L. Silveira, A.P. Fontenot, R.T. Sawyer, E. Wilcox, and L.S. Newman. 2003b. Influence of MHC class II in susceptibility to beryllium sensitization and chronic beryllium disease. J. Immunol. 171(12):6910-6918.
Mancuso, T.F. 1979. Occupational lung cancer among beryllium workers. Pp. 463-471 in Dusts and Disease, R. Lemen, and J.M. Dement, eds. Park Forest South, IL: Pathotox Publishers.
Mancuso, T.F. 1980. Mortality study of beryllium industry workers’ occupational lung cancer. Environ. Res. 21(1):48-55.
Martyny, J.W., M.D. Hoover, M.M. Mroz, K. Ellis, L.A. Maier, K.L. Sheff, and L.S. Newman. 2000. Aerosols generated during beryllium machining. J. Occup. Environ. Med. 42(1):8-18.
Marx, J.J., Jr., and R. Burrell. 1973. Delayed hypersensitivity to beryllium compounds. J. Immunol. 111(2):590-598.
Mathur, R., S. Sharma, S. Mathur, and A.O. Prakash. 1987. Effect of beryllium nitrate on early and late pregnancy in rats. Bull. Environ. Contam. Toxicol. 38(1):73-77.
McCanlies, E.C., K. Kreiss, M. Andrew, and A. Weston. 2003. HLA-DPB1 and chronic beryllium disease: A HuGE review. Am. J. Epidemiol. 157(5):388-398.
McCanlies, E.C., J.S. Ensey, C.R. Schuler, K. Kreiss, and A. Weston. 2004. The association between HLA-DPB1Glu69 and chronic beryllium disease and beryllium sensitization. Am. J. Ind. Med. 46(2):95-103.
McCanlies, E.C., C.R. Schuler, K. Kreiss, B.L. Frye, J.S. Ensey, and A. Weston. 2007. TNF-α polymorphisms in chronic beryllium disease and beryllium sensitization. J. Occup. Environ. Med. 49(4):446-452.
McCawley, M.A., M.S. Kent, and M.T. Berakis. 2001. Ultrafine beryllium number concentration as a possible metric for chronic beryllium disease risk. Appl. Occup. Environ. Hyg. 16(5):631-638.
Milovanova, T.N. 2007. Comparative analysis between CFSE flow cytometric and tritiated thymidine incorporation tests for beryllium sensitivity. Cytometry B Clin. Cytom. 72B(4):265-275.
Milovanova, T.N., S.H. Popma, S. Cherian, J.S. Moore, and M.D. Rossman. 2004. Flow cytometric test for beryllium sensitivity. Cytometry B Clin. Cytom. 60(1):23-30.
Misra, U.K., G. Gawdi, and S.V. Pizzo. 2002. Beryllium fluoride-induced cell proliferation: A process requiring P21ras-dependent activated signal transduction and NF-κB-dependent gene regulation. J. Leukoc. Biol. 71(3):487-494.
Mitchell, R.N., and E.C. Hyatt. 1957. Beryllium; hazard evaluation and control covering a five-year study. Am. Ind. Hyg. Assoc. Q. 18(3):207-213.
Miyaki, M., N. Akamatsu, T. Ono, and H. Koyama. 1979. Mutagenicity of metal cations in cultured cells from Chinese hamster. Mutat. Res. 68(3):259-263.
Morgareidge, K., G.E. Cox, and D.E. Bailey. 1975. Chronic Feeding Studies of Beryllium Sulfate in Rats: Evaluation of Carcinogenic Potential. Prepared for Alcan Research and Development, Ltd., by Food and Drug Research Laboratories, Inc., Pittsburgh, PA (as cited in EPA 1998a).
Morgareidge, K., G.E. Cox, and M.A. Gallo. 1976. Chronic Feeding Studies with Beryllium in Dogs. Prepared for the Aluminum Company of America, Alcan Research and Development, Ltd., Kawecki-Berylco Industries, and Brush-Wellman Inc., by Food and Drug Research Laboratories, Inc., Food and Drug Research Laboratories, Inc., Pittsburgh, PA (as cited in EPA 1998a).
Mueller, J.J., and D.R. Adolphson. 1979. Corrosion. Pp. 417-433 in Beryllium Science and Technology, Vol. 2, D.R. Floyd, and J.N. Lowe, eds. New York, NY: Plenum Press.
NCRP (National Council on Radiation Protection and Measurements). 1997. Deposition, Retention and Dosimetry of Inhaled Radioactive Substances, NCRP Report No. 125. Bethesda, MD: National Council on Radiation Protection and Measurements.
Newman, L.S. 1996. Immunology, genetics, and epidemiology of beryllium disease. Chest 109(Suppl. 3):40S-42S.
Newman, L.S., and P.A. Campbell. 1987. Mitogenic effect of beryllium sulfate on mouse B lymphocytes but not T lymphocytes in vitro. Int. Arch. Allergy Appl. Immunol. 84(3):223-227.
Newman, L.S., and K. Kreiss. 1992. Nonoccupational beryllium disease masquerading as sarcoidosis: Identification of blood lymphocyte proliferative response to beryllium. Am. Rev. Respir. Dis. 145(5):1212-1214.
Newman, L.S., K. Kreiss, T.E. King, Jr., S. Seay, and P.A. Campbell. 1989. Pathologic and immunologic alterations in early stages of beryllium disease. Am. Rev. Respir. Dis. 139(6):1479-1486.
Newman, L.S., R. Orton, and K. Kreiss. 1992. Serum angiotensin converting enzyme activity in chronic beryllium disease. Am. Rev. Respir. Dis. 146(1):39-42.
Newman, L.S., D.L. Buschman, J.D. Newell, Jr., and D.A. Lynch. 1994. Beryllium disease: Assessment with CT. Radiology 190(3):835-840.
Newman, L.S., M.M. Mroz, L.A. Maier, E.M. Daniloff, and R. Balkissoon. 2001. Efficacy of serial medical surveillance for chronic beryllium disease in a beryllium machining plant. J. Occup. Environ. Health 43(3):231-237.
Newman, L.S., M.M. Mroz, R. Balkissoon, and L.A. Maier. 2005. Beryllium sensitization progresses to chronic beryllium disease: A longitudinal study of disease risk. Am. J. Respir. Crit. Care. Med. 171(1):54-60.
Nickell-Brady, C., F.F. Hahn, G.L. Finch, and S.A. Belinsky. 1994. Analysis of K-ras, p53 and c-raf-1 mutations in beryllium-induced rat lung tumors. Carcinogenesis 15(2):257-262.
Nikula, K.J., D.S. Swafford, M.D. Hoover, M.D. Tohulka, and G.L. Finch. 1997. Chronic granulomatous pneumonia and lymphocytic responses induced by inhaled beryllium metal in A/J and C3H/HeJ mice. Toxicol. Pathol. 25(1):2-12.
NIOSH (National Institute for Occupational Safety and Health). 1972. Occupational Exposure to Beryllium; Criteria for a Recommended Standard. DHEW (HSM) 72-10268. U.S. Department of Health, Education, and Welfare, Health Services and Mental Health Administration, National Institute for Occupational Safety and Health, Rockville, MD.
NIOSH (National Institute for Occupational Safety and Health). 1977. Statement of Edward J. Baier, Deputy Director, National Institute for Occupational Safety and Health, Center for Disease Control, Department of Health, Education, and Welfare. U.S. Department of Labor, Occupational Safety and Health Administration, Public Hearing on the Occupational Standard for Beryllium. August 19, 1977 [online]. Available: http://www.cdc.gov/niosh/pdfs/77-bery.pdf [accessed April 5, 2007].
NIOSH (National Institute for Occupational Safety and Health). 2005. NIOSH Pocket Guide to Chemical Hazards. DHHS (NIOSH) Publication No. 2005-149. U.S. Department of Health and Human Services, Centers for Disease Control and Prevention, National Institute for Occupational Safety and Health [online]. Available: http://www.cdc.gov/niosh/npg/ [accessed April 5, 2007].
Nishioka, H. 1975. Mutagenic activities of metal compounds in bacteria. Mutat. Res. 31(3):185-189.
Novoselova, A.V., and L.R. Batsanova. 1969. Analytical Chemistry of Beryllium. Ann Arbor, MI: Ann Arbor-Humphrey Science Publishers.
NTP (National Toxicology Program). 1999. Report on Carcinogens. Background Document for Beryllium and Beryllium Compounds. Prepared by Technology Planning and Management Corporation, Durham, NC, for the U.S. Department of Health and Human Services, Public Health Service, National Toxicology Program, Research Triangle Park, NC [online]. Available: http://ntp.niehs.nih.gov/ntp/newhomeroc/roc10/BE.pdf [accessed April 26, 2007].
NTP (National Toxicology Program). 2005. Report on Carcinogens, Eleventh Edition. U.S. Department of Health and Human Services, Public Health Service, National Toxicology Program [online]. Available: http://ntp.niehs.nih.gov/ntp/roc/toc11.html [accessed April 5, 2007].
Palmer, B.E., D.G. Mack, A.K. Martin, L.A. Maier, and A.P. Fontenot. 2007. CD57 expression correlates with alveolitis severity in subjects with beryllium-induced disease. J. Allergy Clin. Immunol. 120(1):184-191.
Pappas, G.P., and L.S. Newman. 1993. Early pulmonary physiologic abnormalities in beryllium disease. Am. Rev. Respir. Dis. 148(3):661-666.
Paschal, D.C., B.G. Ting, J.C. Morrow, J.L. Pirkle, R.J. Jackson, E.J. Sampson, D.T. Miller, and K.L. Caldwell. 1998. Trace metals in urine of United States residents: Reference range concentrations. Environ. Res. 76(1):53-59.
Pfeifer, S., R. Bartlett, J. Strausz, S. Haller, and J. Müller-Quernheim. 1994. Beryllium-induced disturbances of the murine immune system reflect some phenomena observed in sarcoidosis. Int. Arch. Allergy Immunol. 104(4):332-339.
Pott, G.B., B.E. Palmer, A.K. Sullivan, L. Silviera, L.A. Maier, L.S. Newman, B.L. Kotzin, and A.P. Fontenot. 2005. Frequency of beryllium-specific, TH1-type cytokine-expressing CD4+ T cells in patients with beryllium-induced disease. J. Allergy Clin. Immunol. 115(5):1036-1042.
Reeves, A.L., and D. Deitch. 1969. Influence of age on the carcinogenic response to beryllium inhalation. Pp. 651-652 in Proceedings of the 16th International Congress on Occupational Health, S. Harishima, ed. Tokyo, Japan: Japan Industrial Safety Association (as cited in EPA 1989a).
Reeves, A.L., D. Deitch, and A.J. Vorwald. 1967. Beryllium carcinogenesis. I. Inhalation exposure of rats to beryllium sulfate aerosol. Cancer Res. 27(3):439-445.
Resnick, H., M. Roche, and W.K. Morgan. 1970. Immunoglobulin concentrations in berylliosis. Am. Rev. Respir. Dis. 101(4):504-510.
Richeldi, L., R. Sorrentino, and C. Saltini. 1993. HLA-DPB1 glutamate 69: A genetic marker of beryllium disease. Science 262(5131):242-244.
Richeldi, L., K. Kreiss, M.M. Mroz, B. Zhen, P. Tartoni, and C. Saltini. 1997. Interaction of genetic and exposure factors in the prevalence of berylliosis. Am. J. Ind. Med. 32(4):337-340.
Robinson, F.R., F. Schaffner, and E. Trachtenberg. 1968. Ultrastructure of the lungs of dogs exposed to beryllium-containing dusts. Arch. Environ. Health 17(2):193-203.
Rogliani, P., M. Amicosante, F. Berretta, C. Dotti, M. Bocchino, K.M. O’Donnell, and C. Saltini. 2004. Role of the HLA-DP GLU 69 and the TNF-α TNF-α2 gene markers in susceptibility to beryllium hypersensitivity. Int. J. Immunopathol. Pharmacol. 17(Suppl. 2):3-10.
Rom, W.N., J.E. Lockey, K.M. Bang, C. Dewitt, and J.E. Johns, Jr. 1983. Reversible beryllium sensitization in a prospective study of beryllium workers. Arch. Environ. Health 38(5):302-307.
Rosenkranz, H.S., and L.A. Poirier. 1979. Evaluation of the mutagenicity and DNA-modifying activity of carcinogens and noncarcinogens in microbial systems. J. Natl. Cancer Inst. 62(4):873-891.
Rosenman, K., V. Hertzberg, C. Rice, M.J. Reilly, J. Aronchick, J.E. Parker, J. Regovich, and M. Rossman. 2005. Chronic beryllium disease and sensitization at a beryllium processing facility. Environ. Health Perspect. 113(10):1366-1372.
Rossman, M.D. 1996. Chronic beryllium disease: Diagnosis and management. Environ. Health Perspect. 104(Suppl. 5):945-947.
Rossman, M.D., J.A. Kern, J.A. Elias, M.R. Cullen, P.E. Epstein, O.P. Preuss, T.N. Markham, and R.P. Daniele. 1988. Proliferative response of bronchoalveolar lymphocytes to beryllium. A test for chronic beryllium disease. Ann. Intern. Med. 108(5):687-693.
Rossman, M.D., O.P. Preuss, and M.B. Powers, eds. 1991. Beryllium: Biomedical and Environmental Aspects. Baltimore, MD: Williams & Wilkins.
Rossman, M.D., J. Stubbs, C.W. Lee, E. Argyris, E. Magira, and D. Monos. 2002. Human leukocyte antigen class II amino acid epitopes: Susceptibility and progression markers for beryllium hypersensitivity. Am. J. Respir. Crit. Care Med. 165(6):788-794.
Sackett, H.M., L.A. Maier, L.J. Silveira, M.M. Mroz, L.G. Ogden, J.R. Murphy, and L.S. Newman. 2004. Beryllium medical surveillance at a former nuclear weapons facility during cleanup operations. J. Occup. Environ. Med. 46(9):953-961.
Saltini, C., K. Winestock, M. Kirby, P. Pinkston, and R.G. Crystal. 1989. Maintenance of alveolitis in patients with chronic beryllium disease by beryllium-specific helper T cells. N. Engl. J. Med. 320(17):1103-1109.
Saltini, C., M. Kirby, B.C. Trapnell, N. Tamura, and R.G. Crystal. 1990. Biased accumulation of T lymphocytes with “memory”-type CD45 leukocyte common antigen gene expression on the epithelial surface of the human lung. J. Exp. Med. 171(4):1123-1140.
Saltini, C., L. Richeldi, M. Losi, M. Amicosante, C. Voorter, E. van den Berg-Loonen, R.A. Dweik, H.P. Wiedemann, D.C. Deubner, and C. Tinelli. 2001. Major histocompatibility locus genetic markers of beryllium sensitization and disease. Eur. Respir. J. 18(4):677-684.
Sanders, C.L., W.C. Cannon, and G.J. Powers. 1978. Lung carcinogenesis induced by inhaled high-fired oxides of beryllium and plutonium. Health Phys. 35(2):193-199.
Sanderson, W.T., P.K. Henneberger, J. Martyny, K. Ellis, M.M. Mroz, and L.S. Newman. 1999. Beryllium contamination inside vehicles of machine shop workers. Appl. Occup. Environ. Hyg. 14(4):223-230.
Sanderson, W.T., M.R. Petersen, and E.M. Ward. 2001a. Estimating historical exposures of workers in a beryllium manufacturing plant. Am. J. Ind. Med. 39(2):145-157.
Sanderson, W.T., E.M. Ward, K. Steenland, and M.R. Petersen. 2001b. Lung cancer case-control study of beryllium workers. Am. J. Ind. Med. 39(2):133-144.
Sato, H., L. Silveira, T. Fingerlin, K. Dockstader, M. Gillespie, A.L. Lagan, P. Lympany, R.T. Sawyer, R.M. du Bois, K.I. Welsh, and L.A. Maier. 2007. TNF polymorphism and bronchoalveolar lavage cell TNF-α levels in chronic beryllium disease and beryllium sensitization. J. Allergy Clin. Immunol. 119(3):687-696.
Savitz, D.A., E.A. Whelan, and R.C. Kleckner. 1989. Effects of parents’ occupational exposures on risk of stillborn, preterm delivery, and small-for-gestational age infants. Am. J. Epidemiol. 129:1201-1218.
Sawyer, R.T., V.A. Fadok, L.A. Kittle, L.A. Maier, and L.S. Newman. 2000. Beryllium-stimulated apoptosis in macrophage cell lines. Toxicology 149(2-3):129-142.
Sawyer, R.T., L.A. Maier, L.A. Kittle, and L.S. Newman. 2002. Chronic beryllium disease: A model interaction between innate and acquired immunity. Int. Immunopharmacol. 2(2-3):249-261.
Sawyer, R.T., B.J. Day, V.A. Fadok, M. Chiarappa-Zucca, L.A. Maier, A.P. Fontenot, L. Silveira, and L.S. Newman. 2004a. Beryllium-ferritin: Lymphocyte proliferation and macrophage apoptosis in chronic beryllium disease. Am. J. Respir. Cell Biol. 31(4):470-477.
Sawyer, R.T., C.E. Parsons, A.P. Fontenot, L.A. Maier, M.M. Gillespie, E.B. Gottschall, L. Silveira, and L.S. Newman. 2004b. Beryllium-induced tumor necrosis factor-α production by CD4+ T cells is mediated by HLA-DP. Am. J. Respir. Cell Mol. Biol. 31(1):122-130.
Sawyer, R.T., D.R. Dobis, M. Goldstein, L. Velsor, L.A. Maier, A.P. Fontenot, L. Silveira, L.S. Newman, and B.J. Day. 2005. Beryllium-stimulated reactive oxygen species and macrophage apoptosis. Free Radic. Biol. Med. 38(7):928-937.
Sawyer, R.T., A.P. Fontenot, T.A. Barnes, C.E. Parsons, B.C. Tooker, L.A. Maier, M.M. Gillespie, E.B. Gottschall, L. Silveria, J. Hagman, and L.S. Newman. 2007. Beryllium-induced TNA-α production is transcription-dependent in chronic beryllium disease. Am. J. Respir. Cell. Mol. Biol. 36(2):191-200.
Schepers, G.W. 1964. Biological action of beryllium. Reaction of the monkey to inhaled aerosols. Ind. Med. Surg. 33:1-16.
Schepers, G.W., T.M. Durkan, A.B. Delahant, and F.T. Creedon. 1957. The biological action of inhaled beryllium sulfate. A preliminary chornic toxicity study on rats. Arch. Ind. Health 15(1):32-58.
Schlesinger, R.B. 1995. Deposition and clearance of inhaled particles. Pp. 191-224 in Concepts in Inhalation Toxicology, R.O. McClellan and R.F. Henderson, eds. Washington, DC: Taylor and Francis.
Schuler, C.R., M.S. Kent, D.C. Deubner, M.T. Berakis, M. McCawley, P.K. Henneberger, M.D. Rossman, and K. Kreiss. 2005. Process-related risk of beryllium sensitization and disease in a copper-beryllium alloy facility. Am. J. Ind. Med. 47(3):195-205.
Seiler, D.H., C. Rice, R.F. Herrick, and V.S. Hertzberg. 1996. A study of beryllium exposure measurements, Part 2: Evaluation of the components of exposure in the beryllium processing industry. Appl. Occup. Environ. Hyg. 11(2):98-102.
Selivanova, L.N., and T.B. Savinova. 1986. Effects of beryllium chloride and oxide on sexual function of female rats and development of their progeny [in Russian]. Gig. Sanit. 8:44-46 (as cited in ATSDR 2002).
Sendelbach, L.E., and H.P. Witschi. 1987. Bronchoalveolar lavage in rats and mice following beryllium sulfate inhalation. Toxicol. Appl. Pharmacol. 90(2):322-329.
Sendelbach, L.E., A.F. Tryka, and H. Witschi. 1989. Progressive lung injury over a one-year period after a single inhalation exposure to beryllium sulfate. Am. Rev. Respir. Dis. 139(4):1003-1009.
Sharma, P., A. Shah, and S. Shukla. 2002. Protective effect of Tiron (4,5-dihydroxybenzene-1,3-disulfonic acid disodium salt) against beryllium-induced maternal and fetal toxicity in rats. Arch. Toxicol. 6(8):442-448.
Silveira, L., M. Bausch, M. Mroz, L. Maier, and L. Newman. 2003. Beryllium sensitization in the “general population.” Sarcoidosis Vasc. Diffuse Lung Dis. 20:157.
Simmon, V.F. 1979a. In vitro mutagenicity assays of chemical carcinogens and related compounds with Salmonella typhimurium. J. Natl. Cancer Inst. 62(4):893-899.
Simmon, V.F. 1979b. In vitro assays for recombinogenic activity of chemical carcinogens and related compounds with Saccharomyces cerevisiae D3. J. Natl. Cancer Inst. 62(4):901-909.
Simmon, V.F., H.S. Rosenkranz, E. Zeiger, and L.A. Poirier. 1979. Mutagenic activity of chemical carcinogens and related compounds in the intraperitoneal host-mediated assay. J. Natl. Cancer Inst. 62(4):911-918.
Skilleter, D.N., N.C. Barrass, and R.J. Price. 1991. C-myc expression is maintained during the G1 phase cell cycle block produced by beryllium. Cell Prolif. 24(2):229-237.
Spencer, H.C., R.H. Hook, J.A. Blumenshine, S.B. McCollister, S.E. Sadek, and J.C. Jones. 1968. Toxicological Studies on Beryllium Oxides and Beryllium-Containing Exhaust Products. AMRL-TR-68-148. Aerospace Medical Research Laboratories, Wright-Patterson AFB, OH.
Stange, A.W., D.E. Hilmas, and F.J. Furman. 1996a. Possible health risks from low level exposure to beryllium. Toxicology 111(1-3):213-224.
Stange, A.W., F.J. Furman, and D.E. Hilmas. 1996b. Rocky Flats beryllium health surveillance. Environ. Health Perspect. 104(Suppl. 5):981-986.
Stange, A.W., D.E. Hilmas, F.J. Furman, and T.R. Gatliffe. 2001. Beryllium sensitization and chronic beryllium disease at a former nuclear weapons facility. Appl. Occup. Environ. Hyg. 16(3):405-417.
Stange, A.W., F.J. Furman, and D.E. Hilmas. 2004. The beryllium lymphocyte proliferation test: Relevant issues in beryllium health surveillance. Am. J. Ind. Med. 46(5):453-462.
Stanton, M.L., P.K. Henneberger, M.S. Kent, D.C. Deubner, K. Kreiss, and C.R. Schuler. 2006. Sensitization and chronic beryllium disease among workers in copper-beryllium distribution centers. J. Occup. Environ. Med. 48(2):204-211.
Steele, V.E., B.P. Wilkinson, J.T. Arnold, and R.S. Kutzman. 1989. Study of beryllium oxide genotoxicity in cultured respiratory epithelial cells. Inhal. Toxicol. 1(1):95-110.
Steenland, K., and E. Ward. 1991. Lung cancer incidence among patients with beryllium disease: A cohort mortality study. J. Natl. Cancer Inst. 83(19):1380-1385.
Stefaniak, A.B., V.M. Weaver, M. Cadorette, L.G. Puckett, B.S. Schwartz, L.D. Wiggs, M.D. Jankowski, and P.N. Breysse. 2003a. Summary of historical beryllium uses and airborne concentration levels at Los Alamos National Laboratory. Appl. Occup. Environ. Hyg. 18(9):708-715.
Stefaniak, A.B., M.D. Hoover, R.M. Dickerson, E.J. Peterson, G.A. Day, P.N. Breysse, M.S. Kent, and R.C. Scripsick. 2003b. Surface area of respirable beryllium metal, oxide, and copper alloy aerosols and implications for assessment of exposure risk of chronic beryllium disease. Am. Ind. Hyg. Assoc. J. 64(3):297-305.
Stefaniak, A.B., R.A. Guilmette, G.A.Day, M.D. Hoover, P.N. Breysse, and R.C. Scripsicck. 2005. Characterization of phagolysosomal stimulant fluid for study of beryllium aerosol particle dissolution. Toxicol. In Vitro 19(1):123-134.
Stefaniak, A.B., G.A. Day, M.D. Hoover, P.N. Breysse, and R.C. Scripsick. 2006. Differences in dissolution behavior in a phagolysosomal stimulant fluid for single-constituent and multi-constituent materials associated with beryllium sensitization and chronic beryllium disease. Toxicol. In Vitro 20(1):82-95.
Sterner, H.E., and M. Eisenbud. 1951. Epidemiology of beryllium intoxication. Arch. Ind. Hyg. Occup. Med. 4(2):123-151.
Stoeckle, J.D., H.L. Hardy, and A.L. Weber. 1969. Chronic beryllium disease. Long-term follow-up of sixty cases and selective review of the literature. Am. J. Med. 46(4):545-561.
Stokinger, H.E., G.F. Sprague III, R.H. Hall, N.J. Ashenburg, J.K. Scott, and L.T. Steadman. 1950. Acute inhalation toxicity of beryllium. I. Four definitive studies of beryllium sulfate at exposure concentrations of 100, 50, 10 and 1 mg per cubic meter. Arch. Ind. Hyg. Occup. Med. 1(4):379-397.
Sussman, V.H., J. Lieben, and J.G. Cleland. 1959. An air pollution study of a community surrounding a beryllium plant. Am. Ind. Hyg. Assoc. J. 20:504-508.
Swafford, D.S., S.K. Middleton, W.A. Palmisano, K.J. Nikula, J. Tesfaigzi, S.B. Baylin, J.G. Herman, and S.A. Belinsky. 1997. Frequent aberrant methylation of p16INK4a in primary rat lung tumors. Mol. Cell. Biol. 17(3):1366-1374.
Tan, M.H., C.A. Commens, L. Burnett, and P.J. Snitch. 1996. A pilot study on the percutaneous absorption of microfine titanium dioxide from sunscreens. Australas J. Dermatol. 37(4):185-187.
Tarlo, S.M., K. Rhee, E. Powell, E. Amer, L. Newman, G. Liss, and N. Jones. 2001. Marked tachypnea in siblings with copper beryllium disease due to copper-beryllium alloy. Chest 119(2):647-650.
Thorat, D.D., T.N. Mahadevan, and D.K. Ghosh. 2003. Particle size distribution and respiratory deposition estimates of beryllium aerosols in an extraction and processing plant. Am. Ind. Hyg. Assoc. J. 64(4):522-527.
Tinkle, S.S., and L.S. Newman. 1997. Beryllium-stimulated release of tumor necrosis factor-α, interleukin-6, and their soluble receptors in chronic beryllium disease. Am. J. Respir. Crit. Care Med. 156(6):1884-1891.
Tinkle, S.S., P.W. Schwitters, and L.S. Newman. 1996. Cytokine production by bronchoalveolar lavage cells in chronic beryllium disease. Environ. Health Perspect. 104(Suppl. 5):969-971.
Tinkle, S.S., L.A. Kittle, B.A. Schumacher, and L.S. Newman. 1997. Beryllium induces IL-2 and IFN-γ in berylliosis. J. Immunol. 158(1):518-526.
Tinkle, S.S., J.M. Antonini, B.A. Rich, J.R. Roberts, R. Salmen, K. DePree, and E.J. Adkins. 2003. Skin as a route of exposure and sensitization in chronic beryllium disease. Environ. Health Perspect. 111(9):1202-1208.
TRI99(Toxic Release Inventory). 2002. Toxic Chemical Release Inventory. TRI on-site and off-site releases (in pounds), all facilities (of 8) for releasing beryllium, all industries. National Library of Medicine, National Toxicology Information Program, Bethesda, MD [online]. Available: http://www.epa.gov./triexplorer/chemical/htm (as cited by ATSDR 2002).
Tsujii, H., and K. Hashishima. 1979. The effect of the administration of trace amounts of metals to pregnant mice upon behavior and learning of their offspring [in Japanese]. Shinshu Daigaku Nogakubu Kiyo (as cited in ATSDR 2002).
Ulitzur, S., and M. Barak. 1988. Detection of genotoxicity of metallic compounds by the bacterial bioluminescence test. J. Biolumin. Chemilumin. 2(2):95-99.
Vainio, H., and P. Kleihues. 1994. IARC Working Group of Carcinogenicity of Beryllium [letter]. J. Occup. Med. 36(10):1068-1069.
Van Ordstrand, H.S., R. Hughes, and M.G. Carmody. 1943. Chemical pneumonia in workers extracting beryllium oxide. Cleve. Clin. Quart. 10:10-18.
Van Orstrand, H.S., R. Hughes, J.M. DeNardi, and M.G. Carmody. 1945. Beryllium poisoning. J. Am. Med. Assoc. 129(16):1084-1090.
Vegni-Talluri, M., and V. Guiggiani. 1967. Action of beryllium ions on primary cultures of swine cells. Carylogia 20:355-367 (as cited in EPA 1998a).
Viet, S.M., J. Torma-Krajewski, and J. Rogers. 2000. Chronic beryllium disease and beryllium sensitization at Rocky Flats: A case-control study. Am. Ind. Hyg. Assoc. J. 61(2):244-254.
Vilaplana, J., C. Ramaguera, and F. Grimalt. 1992. Occupational and non-occupational allergic contact dermatitis from beryllium. Contact Dermatitis 26(5):295-298.
Vorwald, A.J. 1968. Biologic manifestations of toxic inhalants in monkeys. Pp. 222-228 in Use of Nonhuman Primates in Drug Evaluation, H. Vagtbor, ed. Austin, TX: University of Texas Press.
Vorwald, A.J., and A.L. Reeves. 1959. Pathologic changes induced by beryllium compounds. Arch. Ind. Health 19(2):190-199.
Vorwarld, A.J., A.L. Reeves, and E.C.J. Urban. 1966. Experimental beryllium toxicology. Pp. 201-234 in Beryllium, Its Industrial Hygiene Aspects, H.E. Stokinger, ed. New York: Academic Press.
Votto, J.J., R.W. Barton, M.A. Gionfriddo, S.R. Cole, J.R. McCormick, and R.S. Thrall. 1987. A model of pulmonary granulomata induced by beryllium sulfate in the rat. Sarcoidosis 4(1):71-76.
Wagner, W.D., D.H. Groth, J.L. Holtz, G.E. Madden, and H.E. Stokinger. 1969. Comparative chronic inhalation toxicity of beryllium ores, bertrandite and beryl, with production of pulmonary tumors by beryl. Toxicol. Appl. Pharmacol. 15:10-29.
Wagoner, J.K., P.F. Infante, and D.L. Bayliss. 1980. Beryllium: An etiologic agent in the induction of lung cancer, nonneoplastic respiratory disease, and heart disease among industrially exposed workers. Environ. Res. 21(1):15-34.
Wang, Z., P.S. White, M. Petrovic, O.L. Tatum, L.S. Newman, L.A. Maier, and B.L. Marrone. 1999. Differential susceptibilities to chronic beryllium disease contributed by different Glu69 HLA-DPB1 and -DPA1 alleles. J. Immunol. 163(3):1647-1653.
Wang, Z., G.M. Farris, L.S. Newman, Y. Shou, L.A. Maier, H.N. Smith, and B.L. Marrone. 2001. Beryllium sensitivity is linked to HLA-DP genotype. Toxicology 165(1):27-38.
Ward, E., A. Okun, A. Ruder, M. Fingerhut, and K. Steenland. 1992. A mortality study of workers at seven beryllium processing plants. Am. J. Ind. Med. 22(6):885-904.
Weber, A.L., J.D. Stoeckle, and H.L. Hardy. 1965. Roentgenologic patterns in long-standing beryllium disease; report of 8 cases. Am. J. Roentgenol. Radium Ther. Nucl. Med. 93:879-890.
Welch, L., K. Ringen, E. Bingham, J. Dement, T. Takaro, W. McGowan, A. Chen, and P. Quinn. 2004. Screening for beryllium disease among construction trade workers at Department of Energy nuclear sites. Am. J. Ind. Med. 46(3):207-218.
Weston, A., J. Snyder, E.C. McCanlies, C.R. Schuler, M.E. Andrew, K. Kreiss, and E. Demchuk. 2005. Immunogenetic factors in beryllium sensitization and chronic beryllium disease. Mutat. Res. 592(1-2):68-78.
Williams, G.M., M.F. Laspia, and V.C. Dunkel. 1982. Reliability of the hepatocyte primary culture/DNA repair test in testing of coded carcinogens and noncarcinogens. Mutat. Res. 97(5):359-370.
Williams, G.M., H. Mori, and C.A. McQueen. 1989. Structure-activity relationships in the rat hepatocyte DNA-repair test for 300 chemicals. Mutat. Res. 221(3):263-286.
Yoshida, T., S. Shima, K. Nagaoka, H. Taniwaki, A. Wada, H. Kurita, and K. Morita. 1997. A study on the beryllium lymphocyte transformation test and the beryllium levels in working environment. Ind. Health 35(3):374-379.
Zakour, R.A., and B.W. Glickman. 1984. Metal-induced mutagenesis in the lacI gene of Escherichia coli. Mutat. Res. 126(1):9-18.
Zielinski, J.F. 1961. Seven-year experience summaries of beryllium air pollution in a modern alloy foundry. Pp. 592-600 in NIOSH Workshop on Beryllium. Cincinnati, OH: Kettering Laboratory, University of Cincinnati.
